Article

Mortality following development of breast cancer while using oestrogen or oestrogen plus progestin: a computer record-linkage study.

Research and Evaluation Department, Kaiser Permanente Southern California, Pasadena, 91101, USA.
British Journal of Cancer (Impact Factor: 4.82). 09/2005; 93(4):392-8. DOI: 10.1038/sj.bjc.6602701
Source: PubMed

ABSTRACT The literature on the relationship between breast cancer mortality and postmenopausal oestrogen and combined oestrogen/progestin therapy is seemingly contradictory. This study explored survival after exposure to oestrogen or oestrogen plus progestin at or in the year prior to breast cancer diagnosis. Information on patients first diagnosed with invasive breast cancer between 1993 and 1998 was linked with outpatient pharmacy data from 1992 to 2000. Patients were classified according to use of oestrogen alone or oestrogen plus progestin at or in the year prior to diagnosis. Compared to nonusers, and adjusting for age at diagnosis, race/ethnicity, tumour size and grade, oestrogen receptor status, surgery status, and chemotherapy and hormone therapy for breast cancer treatment, oestrogen plus progestin users had lower all-cause mortality (stage I hazard ratio (HR) = 0.69, 95% confidence interval (CI)= 0.48-0.99; stage II HR = 0.53, 95% CI = 0.39-0.72) and breast cancer mortality (stage I HR = 0.52, 95% CI = 0.26-1.04; stage II HR = 0.69, 95% CI = 0.48-0.98). Oestrogen users experienced little or no survival benefit for all-cause mortality (stage I HR = 1.04, 95% CI = 0.77-1.42; stage II HR = 0.86, 95% CI = 0.65-1.14) or breast cancer mortality (stage I HR = 1.23, 95% CI 0.72-2.10; stage II HR = 1.01, 95% CI 0.72-1.41). Our findings suggest, relative to nonusers, a lower risk of death from all causes and from breast cancer in patients who were diagnosed with breast cancer while exposed to oestrogen plus progestin, but not in patients exposed to oestrogen only.

0 Bookmarks
 · 
46 Views
  • Gynécologie Obstétrique & Fertilité 01/2008; 36(1):98-103. DOI:10.1016/j.gyobfe.2007.11.008 · 0.58 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: Digoxin use is associated with increased incidence of breast and uterus cancers. We postulated that digoxin use might affect tumor characteristics and increase relapse risk in women with breast cancer. METHODS: Incident breast cancer cases in Danish women (N= 49,312; 1995-2008) were identified. Analyses were conducted in women 20-74 years old. Relapse hazard ratios (HR) were compared in women using and not-using digoxin, adjusting for age, calendar period, protocol, tumor size, nodal involvement, histology grade, estrogen-receptor (ER) status, and anti-estrogen therapy in Cox regression models. RESULTS: 45 relapses occurred in women already using digoxin at breast cancer diagnosis (1,487 person-years). 24 relapses occurred in women later starting digoxin (384 person-years). At diagnosis, tumors in digoxin users were more likely ER+ (85.4% vs. 78.6%; p=0.002) and have Grade 1 ductal histology, compared to non-users (37.2% vs. 25.7%; p=0.004). Overall relapse HR in digoxin users was 1.13 (95% confidence interval: 0.88-1.46) compared to non-users. Relapse risk in digoxin users was significantly increased in the first year (2.19; 1.26-3.78) but not thereafter (0.99; 0.74-1.32) (p=0.02 for difference in HRs). First-year relapse hazard was high in digoxin-using women with ER+ tumors (2.51; 1.39-4.55) but not ER- tumors (0.72; 0.10-5.27). Recurrence hazard was not significantly changed among digoxin-using women also using tamoxifen. CONCLUSIONS: Breast cancers arising in digoxin-using women had better prognostic features. After adjustment for markers, overall breast cancer relapse risk in digoxin users was not increased significantly, although recurrence hazards for ER+ tumors were higher in the first year following diagnosis.
    Breast cancer research: BCR 02/2013; 15(1):R13. DOI:10.1186/bcr3386 · 5.88 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background In the Women's Health Initiative (WHI) randomized trial, estrogen plus progestin increased both breast cancer incidence and mortality. In contrast, most observational studies associate estrogen plus progestin with favorable prognosis breast cancers. To address differences, a cohort of WHI observational study participants with characteristics similar to the WHI clinical trial was studied.Methods We identified 41 449 postmenopausal women with no prior hysterectomy and mammogram negative within 2 years who were either not hormone users (n = 25 328) or estrogen and progestin users (n = 16 121). Multivariable-adjusted Cox proportional hazard regression was used to calculate hazard ratios (HRs) with 95% confidence intervals (CI). All statistical tests were two-sided.ResultsAfter a mean of 11.3 (SD = 3.1) years, with 2236 breast cancers, incidence was higher in estrogen plus progestin users than in nonusers (0.60% vs 0.42%, annualized rate, respectively; HR = 1.55, 95% CI = 1.41 to 1.70, P < .001). Women initiating hormone therapy closer to menopause had higher breast cancer risk with linear diminishing influence as time from menopause increased (P < .001). Survival after breast cancer, measured from diagnosis, was similar in combined hormone therapy users and nonusers (HR = 1.03, 95% CI = 0.79 to 1.35). On a population basis, there were somewhat more deaths from breast cancer, measured from cohort entry (HR = 1.32, 95% CI = 0.90 to 1.93, P = .15), and more all-cause deaths after breast cancer (HR = 1.65, 95% CI = 1.29 to 2.12, P < .001) in estrogen plus progestin users than in nonusers.Conclusions Consistent with WHI randomized trial findings, estrogen plus progestin use is associated with increased breast cancer incidence. Because prognosis after diagnosis on combined hormone therapy is similar to that of nonusers, increased breast cancer mortality can be expected.
    CancerSpectrum Knowledge Environment 03/2013; DOI:10.1093/jnci/djt043 · 14.07 Impact Factor

Full-text (2 Sources)

Download
24 Downloads
Available from
May 31, 2014